PMID- 35256559
OWN - NLM
STAT- MEDLINE
DCOM- 20220530
LR  - 20230914
IS  - 1473-5849 (Electronic)
IS  - 0955-8810 (Linking)
VI  - 33
IP  - 4
DP  - 2022 Jun 1
TI  - Pharmacological activation of kappa opioid receptors in the nucleus accumbens 
      core and ventral tegmental area increases the aversive effects of nicotine.
PG  - 266-281
LID - 10.1097/FBP.0000000000000675 [doi]
AB  - Aversive effects of nicotine play an important role in the development of 
      nicotine dependence. However, neural substrates and/or brain regions that play a 
      role in the aversive effects of nicotine have not been fully identified. Previous 
      work done in our laboratory showed that systemic administration of kappa opioid 
      receptors (KORs) agonist +/-U50488 increased the aversive effects of nicotine. In 
      this study, we assessed the effects of KOR activation in specific brain regions, 
      namely, the nucleus accumbens (NAcc) core and ventral tegmental area (VTA) on the 
      aversive effects of nicotine using the conditioned taste aversion model. Separate 
      groups of Wistar rats were implanted with cannulae above either the NAcc core or 
      the VTA. KOR agonist (+/-U50488) was bilaterally infused in the NAcc core (0, 0.3, 
      and 3 ug/0.5 ul/side) or VTA (0, 0.3, 1.5, and 3 ug/0.5 ul/side) prior to 
      receiving nicotine (0.4 mg/kg, base; s.c.) during conditioning. Bilateral 
      infusion of the KOR agonist (3 ug/0.5 ul/side) in the NAcc core or the VTA 
      increased the aversive effects of nicotine compared with respective saline 
      controls. Together, these results suggest that pharmacological activation of the 
      KORs in the NAcc core and VTA dose dependently modulate the aversive effects of 
      nicotine. Because aversive effects of nicotine determine susceptibility to 
      development of nicotine dependence, we can conclude that KOR activity in the NAcc 
      and VTA after administration of nicotine may determine susceptibility to the 
      development of nicotine dependence.
CI  - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Pham, Han
AU  - Pham H
AD  - Department of Pharmaceutical and Biomedical Sciences, The Raabe College of 
      Pharmacy, Ohio Northern University, Ada, Ohio, USA.
FAU - Seeley, Sarah L
AU  - Seeley SL
FAU - D'Souza, Manoranjan S
AU  - D'Souza MS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220307
PL  - England
TA  - Behav Pharmacol
JT  - Behavioural pharmacology
JID - 9013016
RN  - 0 (Receptors, Opioid, kappa)
RN  - 67198-13-4 
      (3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, 
      (trans)-Isomer)
RN  - 6M3C89ZY6R (Nicotine)
SB  - IM
MH  - 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, 
      (trans)-Isomer/pharmacology
MH  - Animals
MH  - Nicotine/pharmacology
MH  - Nucleus Accumbens/metabolism
MH  - Rats
MH  - Rats, Wistar
MH  - Receptors, Opioid, kappa/metabolism
MH  - *Tobacco Use Disorder
MH  - *Ventral Tegmental Area
EDAT- 2022/03/09 06:00
MHDA- 2022/05/31 06:00
CRDT- 2022/03/08 05:36
PHST- 2022/03/09 06:00 [pubmed]
PHST- 2022/05/31 06:00 [medline]
PHST- 2022/03/08 05:36 [entrez]
AID - 00008877-202206000-00005 [pii]
AID - 10.1097/FBP.0000000000000675 [doi]
PST - ppublish
SO  - Behav Pharmacol. 2022 Jun 1;33(4):266-281. doi: 10.1097/FBP.0000000000000675. 
      Epub 2022 Mar 7.